Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Liabilities (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Total Liabilities for 12 consecutive years, with $431.0 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 1.27% year-over-year to $431.0 million; the TTM value through Mar 2026 reached $431.0 million, up 1.27%, while the annual FY2025 figure was $465.1 million, 6.5% up from the prior year.
  • Total Liabilities hit $431.0 million in Q1 2026 for Syndax Pharmaceuticals, down from $465.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $465.1 million in Q4 2025 and bottomed at $21.6 million in Q3 2022.
  • Average Total Liabilities over 5 years is $181.4 million, with a median of $51.1 million recorded in 2024.
  • Year-over-year, Total Liabilities crashed 48.98% in 2023 and then surged 929.65% in 2025.
  • Syndax Pharmaceuticals' Total Liabilities stood at $29.8 million in 2022, then skyrocketed by 97.01% to $58.7 million in 2023, then skyrocketed by 644.14% to $436.7 million in 2024, then rose by 6.5% to $465.1 million in 2025, then dropped by 7.32% to $431.0 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $431.0 million, $465.1 million, and $436.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.